Lexiscan (Regadenoson) - Summary

LEXISCAN SUMMARY

Regadenoson is an A_2A adenosine receptor agonist that is a coronary vasodilator [ see Clinical Pharmacology ].

Lexiscan™ (regadenoson) injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress.

See all Lexiscan indications & dosage >>

LEXISCAN NEWS HIGHLIGHTS

Published Studies Related to Lexiscan (Regadenoson)

Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial. [2008.05]

Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial (RegCOPD trial). [2008.05]

Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. [2007.09]

A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. [2006]

Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging. [2005.12.06]

more >>

Clinical Trials Related to Lexiscan (Regadenoson)

Comparison of Dobutamine and Regadenoson Stress Cardiac MR [Not yet recruiting]

more >>